Exploring the molecular approach of COX and LOX in Alzheimer’s and Parkinson’s disorder
Kumar A, Behl T, Jamwal S, Kaur I, Sood A, Kumar P. Exploring the molecular approach of COX and LOX in Alzheimer’s and Parkinson’s disorder. Molecular Biology Reports 2020, 47: 9895-9912. PMID: 33263931, DOI: 10.1007/s11033-020-06033-x.Peer-Reviewed Original ResearchConceptsParkinson's diseaseDocosahexaenoic acidAlzheimer's diseaseArachidonic acidLipid mediatorsAnti-inflammatory actionAppropriate therapeutic optionPro-inflammatory eicosanoidsProduction of eicosanoidsResolution of inflammationRole of AACOX-2 enzymeLOX pathwayNeuroinflammatory responseNeuroinflammatory eventsTherapeutic optionsAD patientsCytokine secretionEpidemiological studiesLeukocyte traffickingNF-κBEicosanoid productionBrain disordersNeurological disordersCyclooxygenasePPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders
Jamwal S, Blackburn J, Elsworth JD. PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacology & Therapeutics 2020, 219: 107705. PMID: 33039420, PMCID: PMC7887032, DOI: 10.1016/j.pharmthera.2020.107705.Peer-Reviewed Original ResearchConceptsNeurodegenerative disordersParkinson's diseaseAlzheimer's diseaseParaoxonase 2Mitochondrial biogenesisNeurodegenerative diseasesHuntington's diseasePeroxisome proliferator-activated receptorProliferator-activated receptorPotential therapeutic targetDevastating neurological disorderFunction of neuronsPeroxisome proliferator-activated receptor gamma co-activator-1 alphaPharmacological-based therapiesSymptomatic treatmentCurrent therapiesClinical trialsLigand-inducible transcription factorsTherapeutic targetNeurological disordersDiseasePPARγ modulatorsProgressive lossMitochondrial dysfunctionPromising target